Literature DB >> 16222434

L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Norio Ogawa1, Masato Asanuma, Ikuko Miyazaki, Francisco J Diaz-Corrales, Ko Miyoshi.   

Abstract

With regard to the mechanism of selective dopaminergic neuronal death, experimental results of studies on the neurotoxicity of MPTP and rotenone indicate that degeneration of dopamine neurons is closely related to mitochondrial dysfunction, inflammatory process and oxidative stress, particularly with regard to the generation of quinones as dopamine neuron-specific oxidative stress. Thus, it is now clear that the presence of high levels of discompartmentalized free dopamine in dopaminergic neurons may explain the specific vulnerability of dopaminergic neurons through the generation of highly toxic quinones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222434     DOI: 10.1007/s00415-005-4006-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  98 in total

Review 1.  Failure of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  K S McNaught; C W Olanow; B Halliwell; O Isacson; P Jenner
Journal:  Nat Rev Neurosci       Date:  2001-08       Impact factor: 34.870

2.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.

Authors:  Y Mizuno; S Ohta; M Tanaka; S Takamiya; K Suzuki; T Sato; H Oya; T Ozawa; Y Kagawa
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

Review 3.  The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.

Authors:  K K Chung; V L Dawson; T M Dawson
Journal:  Trends Neurosci       Date:  2001-11       Impact factor: 13.837

4.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes.

Authors:  S Baez; J Segura-Aguilar; M Widersten; A S Johansson; B Mannervik
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Dopamine induces proteasome inhibition in neural PC12 cell line.

Authors:  J N Keller; F F Huang; E R Dimayuga; W F Maragos
Journal:  Free Radic Biol Med       Date:  2000-11-15       Impact factor: 7.376

6.  Pharmacological characterization of dopamine transport in cultured rat astrocytes.

Authors:  M Inazu; N Kubota; H Takeda; J Zhang; Y Kiuchi; K Oguchi; T Matsumiya
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

7.  Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

Authors:  C Knott; G Stern; G P Wilkin
Journal:  Mol Cell Neurosci       Date:  2000-12       Impact factor: 4.314

8.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

9.  Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.

Authors:  J P Spencer; P Jenner; S E Daniel; A J Lees; D C Marsden; B Halliwell
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

10.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

Authors:  B Pardo; M A Mena; M J Casarejos; C L Paíno; J G De Yébenes
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

View more
  13 in total

1.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

2.  Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.

Authors:  Hironori Yokoyama; Ryohei Yano; Hayato Kuroiwa; Tatsuya Tsukada; Hiroto Uchida; Hiroyuki Kato; Jiro Kasahara; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2010-10-19       Impact factor: 3.584

3.  PDGF-BB protects mitochondria from rotenone in T98G cells.

Authors:  Ricardo Cabezas; Marcos Fidel Avila; Janneth González; Ramon Santos El-Bachá; George E Barreto
Journal:  Neurotox Res       Date:  2014-12-17       Impact factor: 3.911

4.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

5.  Ortho-quinone-enhanced ascorbate oxidation. Combined roles of lipid charge and the magnesium cation.

Authors:  Antonio E Alegría; Pedro Sanchez-Cruz
Journal:  Toxicol Environ Chem       Date:  2008-03-01       Impact factor: 1.437

6.  Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease.

Authors:  Victor S Van Laar; April A Dukes; Michael Cascio; Teresa G Hastings
Journal:  Neurobiol Dis       Date:  2007-11-28       Impact factor: 5.996

7.  Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells.

Authors:  Victor S Van Laar; Amanda J Mishizen; Michael Cascio; Teresa G Hastings
Journal:  Neurobiol Dis       Date:  2009-03-28       Impact factor: 5.996

8.  A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.

Authors:  Ryohei Yano; Hironori Yokoyama; Hayato Kuroiwa; Hiroyuki Kato; Tsutomu Araki
Journal:  J Mol Neurosci       Date:  2009-02-07       Impact factor: 3.444

9.  The neurotropic parasite Toxoplasma gondii increases dopamine metabolism.

Authors:  Emese Prandovszky; Elizabeth Gaskell; Heather Martin; J P Dubey; Joanne P Webster; Glenn A McConkey
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

10.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.